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Metabolomics and lipidomics play an important role in
precision medicine. Global or targeted analyses of metabo-
lites and lipids provide a specific metabolic phenotype, a
“metabotype,” of an individual, which can provide impor-
tant information on their propensity to develop certain dis-
eases or their likely reaction to nutrition or pharmaceuticals.
Metabolomics is increasingly being used in research to look
at the etiology, prognosis, and outcomes of disease or pro-
vide more detailed information on normal human bio-
chemistry. By combining metabolomics data sets with clin-
ical, physiological, or other omics data sets, systems biology
approaches can be used to provide context to the observed
changes. For human populations in particular, the huge
variation in genetics, lifestyle, and other extrinsic factors
means that epidemiologic cohorts are often required to
reach sufficient statistical power to drawmeaningful conclu-
sions. In addition, when disease entities are being studied, it
can take years for enough representative samples to be col-
lected. For these reasons, many metabolomics studies are
reliant on samples collected and stored in either “official”
biobanks (i.e., sample access available to other researchers on
application) or privately stored sample repositories.
Biobanks have grown and been increasingly professional-
ized in the past 20 to 30 years. Many biobanks were origi-
nally started for large-scale genetic analyses, and not all re-
positories have collected biofluids or tissues specifically with
metabolomics analyses in mind. Measurements of individ-
ual metabolites can be highly dependent on collection and
sample storage conditions. Thus, to reliably answer research
questions, we need to have reliable collection and storage of
samples in a form that makes them suitable for robust
metabolomics analyses. To do otherwise invites the intro-
duction of large technical variations in the data set and in-
creases the risk of missing important metabolites that are
contributing to the observed phenotypes or incorrectly at-
tributing a metabolite change owing to technical error to a
biological cause.Much is still unknown about the optimum
way to collect and store biological samples formetabolomics
analyses, especially for the less-well-studied tissues and bio-
fluids such as saliva or feces.Here we consultmetabolomics,
lipids, and biobanking experts to discuss how collection and
storage at biobanks can improve metabolomics and lipido-
mics studies.
What do you think are the most important preana-
lytical steps in collecting samples for biobanking for
metabolomics experiments that contribute to techni-
cal variability in the measurement of analytes? Is this
the same for all sample types?
Tobias Pischon: Based
onmy experience as an ep-
idemiologist and investi-
gator in many large-scale
cohort studies, as a general
rule I think that the more
manual work and activity
by humans that is involved
in the process of collecting
and processing samples,
and the less these proce-
dures are automated, the
higher the likelihood of variability. As such, the collection of
samples itself is often the most critical issue. This issue is
probably particularly relevant for blood samples, in which
the quality of collection heavily depends on the training of
technical staff. For example, in the early phase of studies
(after their initiation), we still occasionally encounter hemo-
lysis in blood samples, which indicates that training and
implementation of blood collection procedures need to be
tightly monitored. Similar issues are of course also relevant
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for other types of samples, such as urine or stool samples, in
which the quality heavily depends on how study volunteers
follow the instructions for collecting the samples. The pro-
cessing steps between samples collection and storage (e.g.,
centrifugation, pipetting) may introduce additional vari-
ability.Automationhelps to reduce variability. For example,
in the German National Cohort health study, pipetting ro-
bots have been installed in all recruitment centers, and the
process of aliquoting samples has been fully automated.
Vidya Velagapudi: In my
opinion, it depends on var-
ious factors. For example, a
lack of harmonization in
the process will increase
technical variability, but es-
tablished quality assurance
and control procedures,
well-documented standard
operating procedures, and
trained professionals will
improve it. The preanalyti-
cal steps vary amongdifferent sample types, such as biofluids
and tissues, in which each requires specialized handling and
storage criteria.
Rima Kaddurah-Daouk:
I agree that methods need
to be very well laid out and
used consistently across
sites involved in the collec-
tion of samples. Using vid-
eos to illustrate methods
and writing detailed proto-
cols can help with this, as
can training everyone at 1
site before collection starts.
Use similar centrifuges if
possible. Also important is operating on ice to keep things
cold and rapidly processing all samples before transferring to
freezers. Record all observations in the processing of samples
for each site. And avoid freeze thawing.
Todd Mitchell: If we
consider biobanking of
tissues, especially if do-
nated after death, I think
the key step is ensuring
that the postmortem in-
terval is as short as possible
and that the samples are
snap frozen as quickly as
possible. There can be a
large increase in oxidative
processes and changes to
metabolites after circulation stops, so it is important to
limit them. Of course, there are other things that are
important, and they do vary depending on tissue. For
example, in the brain it is important to ensure that the
exact region is recorded upon dissection and storage be-
cause the cytoarchitecture varies substantially between
regions.
Michael A. Schmidt: As a
molecular scientist, my
work with humans in ex-
treme environments spans
variable and difficult field
conditions, such as orbital
and suborbital spaceflight,
military Special Forces
operations, athletic teams,
high altitude ascent, and
standard clinical settings.
So, we must be quite at-
tentive to when experimental variance might be intro-
duced. We use a structured approach to address preana-
lytical variance. First, we break the sources down to
variance that may occur at the (a) patient, (b) physician,
and (c) laboratory levels, in which each variable class has
multiple potential contributors. Across these 3 domains,
temperature is among the most crucial elements to con-
trol. Second, we look at each individual source of vari-
ance in terms of whether we should attempt to control it
or merely annotate. This step is necessary as 1 method to
reduce false discoveries when multivariate statistics are
applied to the resulting high-dimensional data sets.
Although there are many potential sources of exper-
imental variance in each class, a foundational set of vari-
ables should be controlled or carefully annotated. For
each class, the following warrant consideration:
Patient: Dietary intake, pharmaceuticals, illicit drugs,
dietary supplements, botanicals, fasting state, physical activ-
ity, occupation, environmental exposure, pregnancy, men-
strual status, disease diagnoses, genetic variants, circadian
cycles.
Physician: Sampling materials, sampling methods,
sampling conditions, sampling hygiene, sampling time of
day, number of sampling days, number of sampling lo-
cations, number and identity of different phlebotomists,
centrifugation, immediate transfer, immediate freezing,
temperature of immediate freezing, transport method
(e.g., dry ice and amount), transport temperature, days of
transport, unusual weather associated with transport
(e.g., high temperature), number of freeze–thaw cycles,
confirmation of each sample identification, identifica-
tion of missing samples.
Laboratory: Sample reception or intake, unpacking,
accessioning, time or speed to storage, temperature of stor-
age, confirmation of sample identification, notation of any
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missing samples, number of freeze–thaw cycles, processing
methods, analytical environment, analytical methods, instru-
ment(s) used, number and identity of chemists involved,
batch processing status (and all related details thereof).
How do you think biobanking is improving experi-
mental design for metabolomics experiments? Are
there any disadvantages to biobanks where samples
are collected with unknown purposes in mind? Is
there a trade-off between flexibility and less-optimum
experimental design?
Michael A. Schmidt: First, greater attention is being given
to dividing specimens into aliquots in anticipation of asking
a series of research questions over time. This method elimi-
nates 1 significant contributor to experimental variance,
which is freeze–thaw cycling. Also, knowledge that a sample
may be stored for extended periods can encourage investi-
gators to probe more deeply into elements that influence
stability over time (e.g., whether to use80 °C or40 °C
for storage, or another option).
Todd Mitchell: The availability of human tissue is in-
valuable. Some experiments, especially those examining
uncommon diseases, would take decades to perform if
biobanking wasn’t available. There is some trade-off be-
tween flexibility and optimum experimental design. For
example, analysis of some bioactive lipids requires strict
collection and storage protocols, making them difficult
to analyze from biobanked tissue.
Rima Kaddurah-Daouk: Use of biobanked materials
has proven to provide great value including in deriving
metabolomics data and biochemical insights. Metabolo-
mics needs to adapt to realities that, within clinical set-
tings, samples might very well have been collected with-
out specific plans as to how they will be used. If there was
a specific purpose for use on collection, then optimized
collection for what is to be measured should have been
attempted. Yet, there is substantial knowledge to be
gained without specifications.
Tobias Pischon: State-of-the-art biobanking should re-
duce parts of the technical variability that are related to
storage conditions of samples. In addition, regarding
metabolomics, it is of course preferable to perform the
analyses within a narrow time frame in a single laboratory
to reduce potential effects related to batch-to-batch or
between-laboratory variation. I would therefore say that
state-of-the-art biobanking is an essential element to con-
duct metabolic experiments for any study that collects
biological samples across study participants over longer
periods. This particularly applies to most larger-scale
studies that involve humans. For example, baseline re-
cruitment in large epidemiologic cohort studies often
takes several years. There is a likely trade-off between
flexibility and specific requirements related to sample
collection and storage. Thus, the better it is known a
priori what metabolomic analyses the samples will be
used for (and which metabolites will be analyzed), the
more sample collection, processing, and storage can be
tailored, which may enhance accuracy and precision.
This reduces the possibility for potential analyses that go
beyond the original planned design. This, however, is an
issue that not only applies to metabolomic experiments
per se but to studies in general.
Michael A. Schmidt: Many samples submitted to bio-
banks are for purposes other than metabolomics experi-
ments and are initially focused on targeted analysis.
Thus, these specimens are frequently not prepared with
attention to the wide range of molecular classes and the
variable stability of molecules within these classes. More-
over, contributors to experimental variance can scale sub-
stantially in the conditions of high variable and low par-
ticipant numbers. Many of these potential contributors
are not controlled for in studies that do not initially set
out to assess the untargeted metabolome.
One of the critical trade-offs can be between broader
feature diversity and the degree to which the sample best
addresses the research question. For example, the
metabolome derived from fecal water versus whole feces
can present notably different metabolome feature pro-
files. Such differences should be weighed in the context of
the biological question being asked. For instance, the
microbial contribution to greater feature diversity in
whole feces may be desirable, if this characteristic is per-
tinent to the research question. However, it can also be
confounding if one wishes to limit the contribution of
ongoing microbial activity to the analytical results. The
choice of fecal water would remove the contribution of
ongoing microbial metabolic activity.
Vidya Velagapudi: Currently, biobanks are improving
the experimental design for metabolomics experiments,
such as sample collection and storage procedures, com-
pared to the past, when the main aim was to extract the
genetic material. I think there are major disadvantages to
biobanks where the samples are collected with unknown
purposes. In the future, if one would like to perform, for
instance, metabolomics analyses, then those samples
might be useless because the analysis requires a tightly
controlled procedure for sample collection and storage.
Is serum or plasma better for metabolomics studies? If
using an anticoagulant, which one and why? Should
we be storing and analyzing whole blood more?
Rima Kaddurah-Daouk: A substantial amount of data
supports the value for profiling of both serum and plasma.
Q&A
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Themetabolome captured in both is not identical, but sim-
ilarities do exist with regard to many metabolites measured.
For example, if one is interested in platelet metabolites like
serotonin, use of serum is better because it captures some of
what platelets produce. However, certain metabolic profil-
ingmethods are validated onEDTAor heparin plasma, and
thus it is preferable if the validated biofluid is used for mea-
surement.Whole blood collectionwould be extremely valu-
able because minimal manipulation by collectors would
minimize variability.
Tobias Pischon: In my experience, most persons in the
metabolomics field recommend using serum, probably
because of a lower likelihood that anticoagulants affect
the metabolites. As such, the answer to this question de-
pends on what metabolites will be measured. We have
done our studies mostly with serum samples, and for
biobanking of samples, I would probably also recom-
mend using serum.One should, however, not neglect the
fact that because of the preparation procedures required,
the use of serummay introduce additional technical vari-
ability, and therefore the preparation needs to be highly
standardized.
Todd Mitchell: I have only used plasma and erythro-
cytes, so I don’t have any experience comparing serum to
plasma. In general, we used EDTA as an anticoagulant.
Blood samples can usually be collected quickly and easily.
In our research in which we are dealing with highly reac-
tive compounds and if a study is specifically focused on
analyzing blood, I think it is better to design your study
around this and collect the samples yourself. That way
you don’t have to compromise, as discussed earlier. Nev-
ertheless, biobanking blood is useful for correlating blood
and tissue biomarkers when other tissues from the same
donor have been collected simultaneously.
Vidya Velagapudi: In our national Metabolomics Core
Facility, we have analyzed mainly serum rather than
plasma samples. There is no clear-cut answer about
which sample type is better for metabolomics analyses
because it mainly depends on which metabolites are to be
analyzed, as mentioned earlier. The most important as-
pect to keep in mind is to be consistent in sample collec-
tion and storage throughout the study. So far, there are
relatively fewer studies on whole blood metabolomics
analyses. Perhaps we should also consider analyzing
whole blood more in future.
Which metabolites or lipids do you think are most
vulnerable to storage changes? What is the longest
length of time you think it is reasonable to store a
biobanked sample and the analysis still be reliable?
Which substrates do you think are most sensitive to
storage changes? Should biobanks be doing anything
different routinely to ameliorate this effect?
Tobias Pischon:We have done our metabolomics anal-
yses on disease risk from samples that were collected in
the 1990s and that have been stored in the vapor phase of
liquid nitrogen since then. These studies worked fine,
and the results were reproducible in other studies. How-
ever, our studies were not specifically designed to inves-
tigate the effect of storage time or condition on metabo-
lite concentrations. Any effect of storage time may, of
course, differ across metabolites. Therefore, I don’t think
that there is a specific maximum for how long such sam-
ples may be stored. However, there is very little literature
on this, and studies are warranted to investigate these
effects in detail.
ToddMitchell: As mentioned above, some of the bioac-
tive lipids, such as proinflammatory and inflammatory-
resolving lipids, are highly reactive and probably need to
be collected on demand.
Vidya Velagapudi: We have done polar metabolomics
analyses on population cohort blood samples that were
collected in the 1980s to check their quality. Samples had
been stored initially at 20 °C then after some time at
70 °C.More than half of the analyzedmetabolites were
unstable compared to our internal quality-control sam-
ples. This implied that maintaining proper storage con-
ditions was crucial for metabolomics analyses.
Are there any samples not being collected routinely by
biobanks that you think should be? Why?
Rima Kaddurah-Daouk: Fecal material for gut micro-
biome studies and saliva contain substantial valuable in-
formation about the influences of microbial biomes on
human health.
Tobias Pischon:There is currently a lot of interest in the
potential role of the gut microbiota in health and disease.
Therefore, the collection of stool samples is something
that should be considered in larger studies.
Vidya Velagapudi: So far, mostly biofluid samples have
been collected at biobanks owing to ease in collection and
preparing the samples for storage. In my opinion, other
sample types like tissues, feces, and dried blood spots
should also be collected. Some disease types, such as can-
cer, mitochondrial disorders, and inflammatory and
bowel disorders have already shown organ-specific bio-
markers that play crucial roles in disease prediction and
treatment outcomes. Thus, circulatory metabolites may
not represent the disease activity and severity, and we
may require organ tissue samples to address some biolog-
Q&A
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ical questions. On the other hand, dried blood spots are
the best choice of sample type, especially when there is no
access to the clinical laboratory or in low economic coun-
tries where there are not enough resources to easily follow
protocols that require rapid processing of blood samples.
Michael A. Schmidt: Many studies of the fecal metag-
enome do not concurrently assess the fecal metabolome.
The proper collection of fecal samples that enables both
metagenome andmetabolome analysis will add consider-
able value to our understanding of health and disease.
Todd Mitchell: The tissues I’m interested in for my re-
search are all being collected by biobanks routinely.
Sometimes patient and/or sample information are not
adequate though.
There is much talk about large-scale studies. What
classifies a study as large scale, and are overall num-
ber of samples or n number per group more important
in this classification?
Michael A. Schmidt: Regardless of whether a large- or
small-scale study, it is becoming increasingly clear that
longitudinal analysis is an important means to address
individual variance. Longitudinal sampling is often con-
sidered with regard to the active study period. However,
there is additional value in serial baseline and end point
measures, so that the baseline and end point results are
not dependent upon a single point in time. For example,
in the NASA Twins Study, 3 baseline and 6 end point
samples were obtained (spanning 120 and 180 days,
respectively).
Rima Kaddurah-Daouk: What constitutes large scale
has evolved as metabolomics tools became more easily
accessible and handling of large samples became possible.
A decade ago we were profiling hundreds of samples and
thought this was large. Currently, we are ready to profile
hundreds of thousands and gearing toward millions, and
that became the new large.
ToddMitchell: As far as I know there is no set definition
to determine if a study is “large scale” and is therefore
somewhat subjective. Personally, I would consider any
study with an “n” in the hundreds as large scale for lip-
idomics, although this number would be small for public
health studies. The “n” per group is by far the more
important factor because that is what determines the
study’s power.
Vidya Velagapudi: I would agree with Todd. In my
experience, the “n” per group is more important than the
overall number of samples in any study because the sam-
ple size is important for the downstream data analysis
statistics.
Tobias Pischon: It is difficult to give an absolute number
for what defines a large-scale study, and I am not sure
whether we need such a definition. Although the number
of samples primarily determines how many analyses can
be conducted, the size of a study is a crucial design ele-
ment that heavily influences the inference that can be
drawn. The necessary size of a study heavily depends
primarily on the study question and on the desired effect
size and precision of results but also on other questions
such as generalizability. It also depends on the trait of
interest and its distribution in the study population. For
example, discrete traits usually require a larger sample size
than quantitative traits. In the field of genomics, most
studies on disease risk have been conducted with case-
control or cross-sectional designs. For metabolomics,
however, this study design is less appropriate because it
cannot differentiate between cause and effect (reverse
causation bias). Thus, metabolic studies that aim to iden-
tify disease risk factors require prospective cohort studies,
in which samples are being collected among participants
who do not yet have the disease in question. Therefore,
the required sample size in these studies depends on the
incidence rate of the disease that one wants to investigate.
This is the prime reason why population-based cohort
studies (i.e., primary prevention settings) require much
larger sample sizes than patient-based cohort studies (i.e.,
secondary prevention). An important reason for the large
sample size required by many metabolomics studies is
that they are often exploratory in nature, and therefore,
multiple testing needs to be taken into account, which
usually requires lower significance levels and larger sam-
ple sizes.
Are there any inherently different inclusion or collec-
tion processes that should be followed when collecting
for a large-scale study or for studies that require very
long collection times (e.g., rare diseases) compared to
a small-scale study?
Rima Kaddurah-Daouk: To maximize knowledge
gained across diseases, it is best to collect under similar
conditions and with the exact same protocols. That
might not be feasible. Vidya has already mentioned the
drive to collect small-volume blood samples like single
blood spots on paper and mailing them from across a
large number of sites. This method would be ideal if
technologies advance enough to make this a robust col-
lection measure for analysis. For deeper studies on or-
phan diseases, it would be useful if multiple samples can
be collected per specification and with optimization for
each area of biochemistry being evaluated, but if not, at
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least 1 sample collected per large study protocol would be
helpful.
Todd Mitchell: Generally, the collection process is sim-
ilar, it is just that correct storage becomes even more
critical for longer term storage.
Vidya Velagapudi: In my opinion, compared to small-
scale studies, when collecting biobank samples for studies
that require a very long time (e.g., rare diseases), we
should focus on maintaining good quality patient regis-
tries. Standardized quality assurance protocols should be
followed to collect good-quality samples. Training is also
a very important component here, i.e., training the bio-
bank or clinical professionals such that all the samples
would be collected in a similar fashion to avoid technical
variability. Harmonization is the key point. In addition,
patient or clinical registries and associated biobank sam-
ple databases should be linked correctly, and a sample
information retrieval system should be present. Another
crucial practical issue is to maintain sufficient funding to
collect and store the samples for a very long time.
Michael A. Schmidt: I previously discussed the variables
that contribute to technical variation in collecting, pro-
cessing, and storing of samples in the answer to the first
question. Although these variables are important in all
research involving clinical chemistry, they tend to scale in
large-scale metabolomics studies. Moreover, accumulat-
ing experimental variables becomes additionally prob-
lematic in metabolomics studies involving small partici-
pant numbers, such as those encountered in astronauts,
athletic teams, military Special Forces, or rare diseases.
Small-scale studies are particularly susceptible to overfit-
ting owing to large variable numbers and small sample
(participant) numbers. An important means to address
this problem is longitudinal analysis with careful annota-
tion of factors that contribute to experimental and bio-
logical variance. Longitudinal sampling is often consid-
ered with regard to the active study period. However,
there is additional value in serial baseline and end point
measures, so that the baseline and end point results are
not dependent on a single point in time, which means
that the experimental design of collection is important.
Although small participant numbers are never ideal,
they may represent the only source of data available from
which to advance certain fields. For example, in the
NASA Twins Study, only 1 individual flew in space,
while his monozygotic twin remained on Earth (n 2).
In this study, samples were collected over 27 months,
including the 340 consecutive days on the International
Space Station. The limiting effect of the small participant
number was partially addressed by longitudinal sam-
pling, a critical component of small “n” studies. Al-
though not a large-scale study, this experiment has pro-
vided the most robust molecular data set to date on any
human in the extreme environment of space (low Earth
orbit).
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